Roivant Sciences Ltd.
$29.41
▲
0.41%
2026-04-22 10:12:13
roivant.com
NMS: ROIV
Explore Roivant Sciences Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$21.16 B
Current Price
$29.41
52W High / Low
$30.33 / $10.01
Stock P/E
—
Book Value
$6.02
Dividend Yield
—
ROCE
-21.06%
ROE
-19.14%
Face Value
—
EPS
$-1.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
750
Beta
1.21
Debt / Equity
2.19
Current Ratio
30.66
Quick Ratio
33.47
Forward P/E
-24.34
Price / Sales
1,516.9
Enterprise Value
$16.47 B
EV / EBITDA
-13.03
EV / Revenue
1,237.7
Rating
Strong Buy
Target Price
$33.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 2. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
| 3. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
| 4. | Edesa Biotech, Inc. | $6.75 | — | $49.5 M | — | -57.24% | -96.39% | $9.37 / $0.72 | $0.56 |
| 5. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 6. | Outlook Therapeutics, Inc. | $0.37 | — | $38.71 M | — | 246.27% | 118.61% | $3.39 / $0.16 | $-0.6 |
| 7. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2 M | 1.57 M | 2.17 M | 7.57 M | 9.02 M | — |
| Operating Profit | -339.15 M | -306.23 M | -284.92 M | -284.96 M | -274.38 M | — |
| Net Profit | -265.89 M | -113.52 M | -223.35 M | -206.47 M | 169.38 M | — |
| EPS in Rs | -0.37 | -0.16 | -0.31 | -0.29 | 0.24 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 29.05 M | 32.71 M | 31.53 M | 55.29 M |
| Operating Profit | -1.11 B | -824.93 M | -809.01 M | -1.21 B |
| Net Profit | -171.98 M | 4.35 B | -1.01 B | -845.26 M |
| EPS in Rs | -0.24 | 6.08 | -1.41 | -1.18 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.44 B | 7.22 B | 2.39 B | 2.59 B |
| Total Liabilities | 249.74 M | 773.95 M | 782.02 M | 523.7 M |
| Equity | 4.69 B | 5.97 B | 1.16 B | 1.66 B |
| Current Assets | 5 B | 6.73 B | 1.8 B | 2.15 B |
| Current Liabilities | 149.41 M | 266.76 M | 272.45 M | 184.37 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -839.45 M | -765.27 M | -843.39 M | -677.73 M |
| Investing CF | -1.77 B | 5.2 B | -44.27 M | 303.3 M |
| Financing CF | -1.22 B | 419.36 M | 499.46 M | 306.79 M |
| Free CF | -844.05 M | -766.65 M | -856.08 M | -695.16 M |
| Capex | -4.6 M | -1.38 M | -12.69 M | -17.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -11.19% | 3.75% | -42.97% | — |
| Earnings Growth % | -103.95% | 531% | -19.37% | — |
| Profit Margin % | -591.96% | 13294.18% | -3200.22% | -1528.89% |
| Operating Margin % | -3833.27% | -2521.71% | -2565.85% | -2191.78% |
| Gross Margin % | 96.86% | 95.11% | 90.38% | 83.78% |
| EBITDA Margin % | -3784.84% | -2454.35% | -2506.05% | -1647.39% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.